학술논문
전자자료 공정이용 안내
우리 대학 도서관에서 구독·제공하는 모든 전자자료(데이터베이스, 전자저널, 전자책 등)는 국내외 저작권법과 출판사와의 라이선스 계약에 따라 엄격하게 보호를 받고 있습니다.
전자자료의 비정상적 이용은 출판사로부터의 경고, 서비스 차단, 손해배상 청구 등 학교 전체에 심각한 불이익을 초래할 수 있으므로, 아래의 공정이용 지침을 반드시 준수해 주시기 바랍니다.
공정이용 지침
- 전자자료는 개인의 학습·교육·연구 목적의 비영리적 사용에 한하여 이용할 수 있습니다.
- 합리적인 수준의 다운로드 및 출력만 허용됩니다. (일반적으로 동일 PC에서 동일 출판사의 논문을 1일 30건 이하 다운로드할 것을 권장하며, 출판사별 기준에 따라 다를 수 있습니다.)
- 출판사에서 제공한 논문의 URL을 수업 관련 웹사이트에 게재할 수 있으나, 출판사 원문 파일 자체를 복제·배포해서는 안 됩니다.
- 본인의 ID/PW를 타인에게 제공하지 말고, 도용되지 않도록 철저히 관리해 주시기 바랍니다.
불공정 이용 사례
- 전자적·기계적 수단(다운로딩 프로그램, 웹 크롤러, 로봇, 매크로, RPA 등)을 이용한 대량 다운로드
- 동일 컴퓨터 또는 동일 IP에서 단시간 내 다수의 원문을 집중적으로 다운로드하거나, 전권(whole issue) 다운로드
- 저장·출력한 자료를 타인에게 배포하거나 개인 블로그·웹하드 등에 업로드
- 상업적·영리적 목적으로 자료를 전송·복제·활용
- ID/PW를 타인에게 양도하거나 타인 계정을 도용하여 이용
- EndNote, Mendeley 등 서지관리 프로그램의 Find Full Text 기능을 이용한 대량 다운로드
- 출판사 콘텐츠를 생성형 AI 시스템에서 활용하는 행위(업로드, 개발, 학습, 프로그래밍, 개선 또는 강화 등)
위반 시 제재
- 출판사에 의한 해당 IP 또는 기관 전체 접속 차단
- 출판사 배상 요구 시 위반자 개인이 배상 책임 부담
'학술논문'
에서 검색결과 22,238건 | 목록
1~20
Conference
2025 International Conference on Artificial Intelligence, Computer, Data Sciences and Applications (ACDSA) Artificial Intelligence, Computer, Data Sciences and Applications (ACDSA), 2025 International Conference on. :1-8 Aug, 2025
Report
IRCCS National Neurological Institute 'C. Mondino' Foundation; Società Italiana per lo Studio delle Cefalee; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Università degli Studi dell'Aquila; University of Roma La Sapienza; Azienda Ospedaliero Universitaria Policlinico Modena; Ospedale di Piove di Sacco; Azienda Ospedaliero-Universitaria di Parma; Azienda Ospedaliera S. Maria della Misericordia; A.O.U. Città della Salute e della Scienza; Cliniche Humanitas Gavazzeni; University of Campania Luigi Vanvitelli; Ospedale Santo Stefano; Azienda Policlinico Umberto I; Auxologico San Luca; Asst Degli Spedali Civili Di Brescia; Carlo Besta Neurological Institute
Effectiveness and Tolerability of Rimegepant as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study (GAINER)
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. Epub 2019 Jul 13.
Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L'Italien G, Morris BA, Coric V, Goadsby PJ. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. Cephalalgia. 2023 Feb;43(2):3331024221141686. doi: 10.1177/03331024221141686.
Iannone LF, Vaghi G, Sebastianelli G, Casillo F, Russo A, Silvestro M, Pistoia F, Volta GD, Cortinovis M, Chiarugi A, Montisano DA, Prudenzano MP, Cevoli S, Mampreso E, Avino G, Romozzi M, Valente M, Fasano C, Battistini S, Granato A, Piella EM, Rainero I, Ornello R, De Icco R; Italian Headache Registry (RICe) Study Group. Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). J Headache Pain. 2025 Jan 6;26(1):4. doi: 10.1186/s10194-024-01935-8.
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.
Croop R, Goadsby PJ, Stock DA, Conway CM, Forshaw M, Stock EG, Coric V, Lipton RB. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019 Aug 31;394(10200):737-745. doi: 10.1016/S0140-6736(19)31606-X. Epub 2019 Jul 13.
Lipton RB, Blumenfeld A, Jensen CM, Croop R, Thiry A, L'Italien G, Morris BA, Coric V, Goadsby PJ. Efficacy of rimegepant for the acute treatment of migraine based on triptan treatment experience: Pooled results from three phase 3 randomized clinical trials. Cephalalgia. 2023 Feb;43(2):3331024221141686. doi: 10.1177/03331024221141686.
Iannone LF, Vaghi G, Sebastianelli G, Casillo F, Russo A, Silvestro M, Pistoia F, Volta GD, Cortinovis M, Chiarugi A, Montisano DA, Prudenzano MP, Cevoli S, Mampreso E, Avino G, Romozzi M, Valente M, Fasano C, Battistini S, Granato A, Piella EM, Rainero I, Ornello R, De Icco R; Italian Headache Registry (RICe) Study Group. Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study). J Headache Pain. 2025 Jan 6;26(1):4. doi: 10.1186/s10194-024-01935-8.
Report
Fondazione Policlinico Universitario Campus Bio-Medico; IRCCS National Neurological Institute 'C. Mondino' Foundation; Società Italiana per lo Studio delle Cefalee; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Università degli Studi dell'Aquila; University of Roma La Sapienza; Azienda Ospedaliero Universitaria Policlinico Modena; Euganea Health Unit, Padua, Italy; Azienda Ospedaliero-Universitaria di Parma; Azienda Ospedaliera S. Maria della Misericordia; A.O.U. Città della Salute e della Scienza; Cliniche Humanitas Gavazzeni; University of Campania Luigi Vanvitelli; Ospedale Santo Stefano; Azienda Policlinico Umberto I; Auxologico San Luca; Asst Degli Spedali Civili Di Brescia
STudio Osservazionale Sull'Efficacia, Sicurezza e tollerabilità di Atogepant in Pazienti Real Life Affetti da Emicrania in Italia (Studio STAR)
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Sep 2;402(10404):775-785. doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26.
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 Sep;19(9):727-737. doi: 10.1016/S1474-4422(20)30234-9.
Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022 Jan;42(1):3-11. doi: 10.1177/03331024211042385. Epub 2021 Sep 14.
Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nezadal T, Guo H, De Abreu Ferreira R, Forero G, Trugman JM. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024 Apr;23(4):382-392. doi: 10.1016/S1474-4422(24)00025-5. Epub 2024 Feb 13.
Vernieri F, Iannone LF, Lo Castro F, Sebastianelli G, De Santis F, Corrado M, Marcosano M, Ornello R, Grazzi L, Montisano DA, De Cesaris F, Munafo A, Fofi L, Doretti A, Vaghi G, Pistoia F, Ferrandi D, Battistini S, Sacco S, Guerzoni S, Altamura C; Italian Headache Registry (RICe) Study Group. Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study). Cephalalgia. 2025 Apr;45(4):3331024251335927. doi: 10.1177/03331024251335927. Epub 2025 Apr 23.
Pozo-Rosich P, Ailani J, Ashina M, Goadsby PJ, Lipton RB, Reuter U, Guo H, Schwefel B, Lu K, Boinpally R, Miceli R, De Abreu Ferreira R, McCusker E, Yu SY, Severt L, Finnegan M, Trugman JM. Atogepant for the preventive treatment of chronic migraine (PROGRESS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023 Sep 2;402(10404):775-785. doi: 10.1016/S0140-6736(23)01049-8. Epub 2023 Jul 26.
Goadsby PJ, Dodick DW, Ailani J, Trugman JM, Finnegan M, Lu K, Szegedi A. Safety, tolerability, and efficacy of orally administered atogepant for the prevention of episodic migraine in adults: a double-blind, randomised phase 2b/3 trial. Lancet Neurol. 2020 Sep;19(9):727-737. doi: 10.1016/S1474-4422(20)30234-9.
Schwedt TJ, Lipton RB, Ailani J, Silberstein SD, Tassorelli C, Guo H, Lu K, Dabruzzo B, Miceli R, Severt L, Finnegan M, Trugman JM. Time course of efficacy of atogepant for the preventive treatment of migraine: Results from the randomized, double-blind ADVANCE trial. Cephalalgia. 2022 Jan;42(1):3-11. doi: 10.1177/03331024211042385. Epub 2021 Sep 14.
Tassorelli C, Nagy K, Pozo-Rosich P, Lanteri-Minet M, Sacco S, Nezadal T, Guo H, De Abreu Ferreira R, Forero G, Trugman JM. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial. Lancet Neurol. 2024 Apr;23(4):382-392. doi: 10.1016/S1474-4422(24)00025-5. Epub 2024 Feb 13.
Vernieri F, Iannone LF, Lo Castro F, Sebastianelli G, De Santis F, Corrado M, Marcosano M, Ornello R, Grazzi L, Montisano DA, De Cesaris F, Munafo A, Fofi L, Doretti A, Vaghi G, Pistoia F, Ferrandi D, Battistini S, Sacco S, Guerzoni S, Altamura C; Italian Headache Registry (RICe) Study Group. Effectiveness and tolerability of atogepant in the prevention of migraine: A real life, prospective, multicentric study (the STAR study). Cephalalgia. 2025 Apr;45(4):3331024251335927. doi: 10.1177/03331024251335927. Epub 2025 Apr 23.
Report
IRCCS National Neurological Institute 'C. Mondino' Foundation; Società Italiana per lo Studio delle Cefalee; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Università degli Studi dell'Aquila; University of Roma La Sapienza; Azienda Ospedaliero Universitaria Policlinico Modena; Ospedale di Piove di Sacco; Azienda Ospedaliero-Universitaria di Parma; Azienda Ospedaliera S. Maria della Misericordia; A.O.U. Città della Salute e della Scienza; Cliniche Humanitas Gavazzeni; University of Campania Luigi Vanvitelli; Ospedale Santo Stefano; Azienda Policlinico Umberto I; Auxologico San Luca; Asst Degli Spedali Civili Di Brescia; Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta
RimegepAnt effectIvenesS and tolErability as Migraine Preventive Treatment: a Prospective, Multicentric, Cohort Study (RAISE)
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021 Jan 2;397(10268):51-60. doi: 10.1016/S0140-6736(20)32544-7. Epub 2020 Dec 15.
Lipton RB, Croop R, Stock EG, Stock DA, Morris BA, Frost M, Dubowchik GM, Conway CM, Coric V, Goadsby PJ. Rimegepant, an Oral Calcitonin Gene-Related Peptide Receptor Antagonist, for Migraine. N Engl J Med. 2019 Jul 11;381(2):142-149. doi: 10.1056/NEJMoa1811090.
Croop R, Lipton RB, Kudrow D, Stock DA, Kamen L, Conway CM, Stock EG, Coric V, Goadsby PJ. Oral rimegepant for preventive treatment of migraine: a phase 2/3, randomised, double-blind, placebo-controlled trial. Lancet. 2021 Jan 2;397(10268):51-60. doi: 10.1016/S0140-6736(20)32544-7. Epub 2020 Dec 15.
Report
IRCCS National Neurological Institute 'C. Mondino' Foundation; Società Italiana per lo Studio delle Cefalee; Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari; Università degli Studi dell'Aquila; University of Roma La Sapienza; Azienda Ospedaliero Universitaria Policlinico Modena; Ospedale di Piove di Sacco; Azienda Ospedaliero-Universitaria di Parma; Azienda Ospedaliera S. Maria della Misericordia; A.O.U. Città della Salute e della Scienza; Cliniche Humanitas Gavazzeni; University of Campania Luigi Vanvitelli; Ospedale Santo Stefano; Azienda Policlinico Umberto I; Auxologico San Luca; Asst Degli Spedali Civili Di Brescia; Carlo Besta Neurological Institute
Effectiveness and Tolerability of Lasmiditan as Acute Migraine Treatment: a Prospective, Multicentric, Cohort Study
Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise SR, Bragg S, Doty EG, Dowsett SA, Lin Q, Krege JH. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia. 2021 Mar;41(3):294-304. doi: 10.1177/0333102421989232. Epub 2021 Feb 4.
Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019 Jul 1;142(7):1894-1904. doi: 10.1093/brain/awz134.
Vaghi G, Iannone LF, Corrado M, De Santis F, Romozzi M, Sebastianelli G, Dalla Volta G, Bolchini M, Burgalassi A, De Cesaris F, Albanese M, Mercuri Biagio N, Ornello R, Sacco S, Pistoia F, Saporito G, Casillo F, Avino G, Granato A, Russo A, Silvestro M, Vollono C, Trimboli M, Doretti A, Valente M, Cevoli S, Mampreso E, Tassorelli C, De Icco R. Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study). Ther Adv Neurol Disord. 2025 Dec 21;18:17562864251381886. doi: 10.1177/17562864251381886. eCollection 2025.
Ashina M, Reuter U, Smith T, Krikke-Workel J, Klise SR, Bragg S, Doty EG, Dowsett SA, Lin Q, Krege JH. Randomized, controlled trial of lasmiditan over four migraine attacks: Findings from the CENTURION study. Cephalalgia. 2021 Mar;41(3):294-304. doi: 10.1177/0333102421989232. Epub 2021 Feb 4.
Goadsby PJ, Wietecha LA, Dennehy EB, Kuca B, Case MG, Aurora SK, Gaul C. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019 Jul 1;142(7):1894-1904. doi: 10.1093/brain/awz134.
Vaghi G, Iannone LF, Corrado M, De Santis F, Romozzi M, Sebastianelli G, Dalla Volta G, Bolchini M, Burgalassi A, De Cesaris F, Albanese M, Mercuri Biagio N, Ornello R, Sacco S, Pistoia F, Saporito G, Casillo F, Avino G, Granato A, Russo A, Silvestro M, Vollono C, Trimboli M, Doretti A, Valente M, Cevoli S, Mampreso E, Tassorelli C, De Icco R. Effectiveness and tolerability of lasmiditan in the acute treatment of migraine: a real-world, prospective, multicentric study (DART study). Ther Adv Neurol Disord. 2025 Dec 21;18:17562864251381886. doi: 10.1177/17562864251381886. eCollection 2025.
Academic Journal
Oveis Jamialahmadi; Endrina Mujica; Lowri Morris; Rosellina Margherita Mancina(Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg; Research Unit of Clinical Medicine and Hepatology, Department of Medicine and Surgery, Università Campus Bio-Medico di Roma; Department of Life Science, Health, and); Ester Ciociola; Sami F. Qadri(Department of Medicine, University of Helsinki and Helsinki University Hospital; Minerva Foundation Institute for Medical Research, Helsinki, Finland); Samantha Maurotti; Francesco Malvestiti; Ruifang Li-Gao; Luisa Ronzoni; Federica Tavaglione; Hannah Maude; Amin Allalou(Division of Visual Information and Interaction, Department of Information Technology, Uppsala University; DanioReadout, Immunology Genetics and Pathology, Uppsala University, Uppsala, Sweden); Anastasia Emmanouilidou; Umberto Vespasiani-Gentilucci(Department of Medicine and Surgery, Università Campus Bio-Medico di Roma; Clinical Medicine and Hepatology Unit, Fondazione Policlinico Universitario Campus Bio-Medico, Rome); Frits Richard Rosendaal; Hannele Yki-Järvinen(Department of Medicine, University of Helsinki and Helsinki University Hospital; Inês Cebola; Luca Valenti(Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy; Precision Medicine – Biological Resource Center and Department of Transfusion Medicine, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Mila); Marcel den Hoed; Stefano Romeo(Department of Molecular and Clinical Medicine, University of Gothenburg, Gothenburg; Clinical Nutrition Unit, Department of Medical and Surgical Sciences, Magna Graecia University, Catanzaro, Italy; Department of Cardiology, Sahlgrenska University Ho)
Clinical and Molecular Hepatology, 31(4), pp.1252-1268 Oct, 2025
Academic Journal
Brillantino Antonio; Iacobellis Francesca; Marano Luigi; Renzi Adolfo; Talento Pasquale; Brusciano Luigi; Gambardella Claudio; Favetta Umberto; Visconte Michele Schiano Di; Monaco Luigi; Grillo Maurizio; Maglio Mauro Natale; Foroni Fabrizio; Palumbo Alessio; Sotelo Maria Laura Sandoval; Vicenzo Luciano; Palladino Elisa; Frezza Giovanna; Menna Maria Paola; Mauro Paolino; Picardi Stefano; Mensorio Mario Massimo; Mosca Vinicio; Bottino Vincenzo; Ioia Giovanna; Rispoli Corrado; Serafino Marco Di; Caruso Martina; Ronza Roberto; Frittoli Barbara; Schettini Daria; Stoppino Luca; Iafrate Franco; Lombardi Giulio; Antropoli Carmine; Cappabianca Salvatore; Docimo Ludovico; Grassi Roberto; Reginelli Alfonso
Annals of Coloproctology, 41(3), pp.207-220 Jun, 2025
Academic Journal
International Journal on Software Tools for Technology Transfer. 25:675-691
Academic Journal
International Journal on Software Tools for Technology Transfer. 25(5-6):765-784
Academic Journal
Di Maida, Fabrizio; Lambertini, Luca; Grosso, Antonio Andrea; Salamone, Vincenzo; Paganelli, Daniele; Di Stefano, Laura; Conte, Francesca; Lipparini, Filippo; Salvi, Matteo; Oriti, Rino; Mari, Andrea; Minervini, Andrea
Journal of Clinical Medicine. December 2025, Vol. 14 Issue 23
Academic Journal
Daria La Cognata; Maria Carla Finocchiaro; Gian Luca Trobia; Alfio Alfonso Azzolina; Vita Antonella Di Stefano
Italian Journal of Pediatrics, Vol 52, Iss 1, Pp 1-9 (2025)
Conference
37th International Conference on Computer Aided Verification, CAV 2025, Zagreb, Croatia Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 15934 LNCS:274-297
Conference
Leveraging Applications of Formal Methods, Verification and Validation, Crete, Greece Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics). 15220 LNCS:333-350
Academic Journal
Il Foro Italiano, 2015 Nov 01. 138(11), 609/610-613/614.
Academic Journal
13 Beijing L. Rev. 738 (2022) / Beijing Law Review, Vol. 13, Issue 4 (December 2022), pp. 738-748
2024-05 Reports of Cases before the Court of Justice and the Court of First Instance 1 (2024) / Reports of Cases before the Court of Justice and the Court of First Instance, Vol. 2024-05, pp. 1-28
2021-01 Reports of Cases before the Court of Justice and the Court of First Instance 1 (2021) / Reports of Cases before the Court of Justice and the Court of First Instance, Vol. 2021-01, pp. 1-18
검색 결과 제한하기
제한된 항목
[검색어] Di Stefano, Luca
발행연도 제한
-
학술DB(Database Provider)
저널명(출판물, Title)
출판사(Publisher)
자료유형(Source Type)
주제어
언어